Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 7,049 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Central Sleep Apnea Comorbid With Opioid Use
Interventions: Acetazolamide, Placebo; Drug
Lead sponsor: Sanjay R Patel; Other
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab 300 mg, Anifrolumab 1000 mg, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 30
States / cities: Birmingham, Alabama • La Jolla, California • La Palma, California + 27 more

Conditions: Generalized Anxiety Disorder
Interventions: Placebo, Vortioxetine, Duloxetine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 781 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 66
States / cities: Anaheim, California • Beverly Hills, California • Fresno, California + 63 more

Conditions: Migraine
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 962 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Sherman Oaks, California • Stamford, Connecticut + 20 more

Conditions: Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
Interventions: lovastatin, placebo, biopsy, laboratory biomarker analysis; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Orange, California • Tampa, Florida • Salt Lake City, Utah

Conditions: COVID-19 Infection
Interventions: Magnesium Citrate plus probiotic; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility
Interventions: Ramipril, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 48
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Psoriatic Arthritis
Interventions: Tofacitinib, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more

Conditions: Cough, Refractory Chronic Cough
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 57
States / cities: Foley, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more

Conditions: Tuberous Sclerosis Complex
Interventions: Ganaxolone, Placebo; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 1 Year to 65 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more

Conditions: Substance Abuse
Interventions: atomoxetine, placebo; Drug
Lead sponsor: Sharon Walsh; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Fragile X Syndrome
Interventions: AFQ056, Placebo, Language Intervention; Drug · Other
Lead sponsor: Elizabeth Berry-Kravis; Other
Eligibility: 32 Months to 6 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 14
States / cities: Davis, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Idiopathic Hypersomnia
Interventions: HBS-301 tablet, Placebo; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 40
States / cities: Birmingham, Alabama • Peoria, Arizona • Redwood City, California + 36 more

Conditions: Coronary Artery Disease
Interventions: MEDI6012, Placebo SC, Placebo IV; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 5 more

Conditions: Moderate Risk of CVD
Interventions: Aspirin (Acetylsalicylic acid, BAYE4465), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 55 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 73
States / cities: Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more

Conditions: Chronic Hepatitis C Infection
Interventions: GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more

Conditions: Alzheimer's Disease
Interventions: BPN14770, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 25 Years to 90 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Non-Alcoholic Steatohepatitis
Interventions: SHP626, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: GLPG1690, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 40 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 47
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 42 more

Conditions: COVID-19 Pneumonia
Interventions: Tocilizumab (TCZ), Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 23
States / cities: La Jolla, California • La Mesa, California • Los Angeles, California + 18 more

Conditions: Osteoarthritis, Knee
Interventions: Pentosan Polysulfate Sodium twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Pentosan Polysulfate Sodium Fixed Dose, Pentosan Polysulfate Sodium once weekly; Drug
Lead sponsor: Paradigm Biopharmaceuticals USA (INC); Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 29
States / cities: Tempe, Arizona • Tucson, Arizona • Cerritos, California + 20 more

Conditions: Kidney Injury, Acute
Interventions: Sodium Nitrate, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cystic Fibrosis
Interventions: VX-661 plus ivacaftor combination, Ivacaftor, Placebo (matched to VX-661 plus ivacaftor combination), Placebo (matched to ivacaftor); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more

Search by objective public record fields.

Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder

A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

Lovastatin in Treating Patients At High Risk of Melanoma

"CHANGE COVID-19 Severity"

Ramipril for the Treatment of Oligospermia

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial

AFQ056 for Language Learning in Children With FXS

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation